Ipragliflozin improved glycaemic control with additional benefits of reductions of body weight and blood pressure in Japanese patients with type 2 diabetes mellitus: BRIGHTEN Study

被引：0
|
作者：
Kashiwagi, A. [1 ]
Takinami, Y. [2 ]
Kazuta, K. [2 ]
Yoshida, S. [2 ]
Utsuno, A. [2 ]
Nagase, I. [2 ]
机构：
[1] Shiga Univ Med Sci, Tokyo, Japan
[2] Astellas Pharma Inc, Tokyo, Japan
来源：
DIABETOLOGIA | 2011年 / 54卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
149
引用
收藏
页码：S68 / S69
页数：2
相关论文
共 50 条
  • [1] Ipragliflozin improves glycemic control in Japanese patients with type 2 diabetes mellitus: the BRIGHTEN study: BRIGHTEN: double-blind randomized study of ipragliflozin to show its efficacy as monotherapy in T2DM patients
    Kashiwagi A.
    Kazuta K.
    Takinami Y.
    Yoshida S.
    Utsuno A.
    Nagase I.
    Diabetology International, 2015, 6 (1) : 8 - 18
  • [2] Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes and inadequate glycaemic control on sitagliptin
    Kaku, Kohei
    Kadowaki, Takashi
    Seino, Yutaka
    Okamoto, Taro
    Shirakawa, Masayoshi
    Sato, Asako
    O'Neill, Edward A.
    Engel, Samuel S.
    Kaufman, Keith D.
    DIABETES OBESITY & METABOLISM, 2021, 23 (09): : 2099 - 2108
  • [3] WEIGHT CHANGE AND BLOOD PRESSURE, LIPIDS AND GLYCAEMIC CONTROL AMONG PATIENTS WITH TYPE 2 DIABETES
    Janghorbani, M.
    Amini, M.
    JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH, 2011, 65 : A255 - A255
  • [4] Benefits of intensified reductions in blood glucose and in blood pressure for patients with type 2 diabetes
    Wang, Nelson
    Zoungas, Sophia
    Chalmers, John
    PRESSE MEDICALE, 2023, 52 (01):
  • [5] Ipragliflozin reduced HbA1c and body weight in Japanese type 2 diabetes patients who have inadequate glycaemic control on sulfonylurea or pioglitazone alone
    Kashiwagi, A.
    Shiga, T.
    Akiyama, N.
    Kazuta, K.
    Ogasawara, H.
    Yoshida, S.
    Ueyama, E.
    Utsuno, A.
    DIABETOLOGIA, 2012, 55 : S302 - S303
  • [6] Therapeutic inertia for glycaemic and blood pressure control in patients with type 2 diabetes mellitus and the cardiovascular consequences
    Paul, S.
    Shaw, J.
    Klein, K.
    DIABETOLOGIA, 2015, 58 : S63 - S63
  • [7] Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight
    Zhang, L.
    Feng, Y.
    List, J.
    Kasichayanula, S.
    Pfister, M.
    DIABETES OBESITY & METABOLISM, 2010, 12 (06): : 510 - 516
  • [8] Effects of ertugliflozin monotherapy or combination therapy on glycaemic control, body weight, and blood pressure in patients with type 2 diabetes: a pooled analysis
    Lauring, B.
    Liu, J.
    Tarasenko, L.
    Terra, S. G.
    Huyck, S.
    Wu, L.
    Pong, A.
    Calle, R. A.
    Gallo, S.
    Darekar, A.
    Mancuso, J. P.
    DIABETOLOGIA, 2018, 61 : S305 - S305
  • [9] Blood pressure control in Japanese hypertensives with or without type 2 diabetes mellitus
    Katayama, S
    Inaba, M
    Morita, T
    Awata, T
    Shimamoto, K
    Kikkawa, R
    HYPERTENSION RESEARCH, 2000, 23 (06) : 601 - 605
  • [10] Non-pharmacologic management of blood pressure, body weight and metabolic control of hypertensive patients with diabetes mellitus type 2
    Santos, R.
    Freitas, J.
    Monteiro, A.
    Macedo, M.
    Rebelo, I.
    JOURNAL OF HYPERTENSION, 2007, 25 : S80 - S80
12345